Working… Menu

Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors (IMMUNOPARP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04675320
Recruitment Status : Recruiting
First Posted : December 19, 2020
Last Update Posted : December 19, 2020
Information provided by (Responsible Party):
Centre Georges Francois Leclerc

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 7, 2021
Estimated Study Completion Date : July 7, 2023